دورية أكاديمية
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
| العنوان: | Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer |
|---|---|
| المؤلفون: | Neuzillet, Cindy, Casadei‐gardini, Andrea, Brieau, Bertrand, Vivaldi, Caterina, Brandi, Giovanni, Tougeron, David, Filippi, Roberto, Vienot, Angélique, Silvestris, Nicola, Pointet, Anne‐laure, Lonardi, Sara, Rousseau, Benoît, Scartozzi, Mario, Dahan, Laetitia, Aprile, Giuseppe, Sourd, Samuel Le, Evesque, Ludovic, Meurisse, Aurélia, Lièvre, Astrid, Vernerey, Dewi |
| المساهمون: | Institut Curie Paris, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Pisa - Università di Pisa, Policlinico S. Orsola-malpighi, Alma Mater Studiorum Università di Bologna = University of Bologna (UNIBO)-Servizio sanitario regionale Emilia-Romagna, Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie ), Università degli studi di Torino = University of Turin (UNITO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), CHU Henri Mondor Créteil, Università degli Studi di Cagliari = University of Cagliari (UniCa), Hôpital de la Timone CHU - APHM (TIMONE), Università degli Studi di Udine - University of Udine Italie, CRLCC Eugène Marquis (CRLCC), UNICANCER, Centre de Lutte contre le Cancer Antoine Lacassagne Nice (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UniCA), Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| المصدر: | ISSN: 0020-7136. |
| بيانات النشر: | HAL CCSD Wiley |
| سنة النشر: | 2020 |
| المجموعة: | Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| مصطلحات موضوعية: | cholangiocarcinoma, combination chemotherapy, monotherapy, overall survival, palliative chemotherapy, [SDV.CAN]Life Sciences [q-bio]/Cancer |
| الوصف: | International audience ; Fluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred option in advanced biliary tract cancer (aBTC) (ABC-06 phase III trial). However, the overall survival (OS) benefit was limited and comparison with FP monotherapy was not available. Our aim was to assess the OS of patients treated with a FP monotherapy compared to a doublet with irinotecan or platinum in L2. We performed a retrospective analysis of two large multicenter prospective cohorts: a French cohort (28 centers) and an Italian cohort (9 centers). All consecutive patients with aBTC receiving FP-based L2 after gemcitabine plus cisplatin/gemcitabine plus oxaliplatin L1 between 2003 and 2016 were included. A subgroup analysis according to performance status (PS) and an exploratory analysis according to platinum sensitivity in L1 were planned. In the French cohort (n = 351), no significant OS difference was observed between the FP monotherapy and doublet groups (median OS: 5.6 vs 6.8 months, P = .65). Stratification on Eastern Cooperative Oncology Group (ECOG) PS showed similar results in PS 0-1 and 2. Median OS was not different between FP monotherapy, platinum- and irinotecan-based doublets (5.6 vs 7.1 vs 6.7 months, P = .68). Similar findings were observed in the Italian cohort (n = 174) and in the sensitivity analysis in pooled cohorts (n = 525). No L2 regimen seemed superior over others in the platinum resistant/refractory or sensitive subgroups. Our results suggest that FP monotherapy is as active as FP doublets in aBTC in L2, regardless of the patient PS and country, and could be a therapeutic option in this setting. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/32525595; hal-02929354; https://univ-rennes.hal.science/hal-02929354Test; https://univ-rennes.hal.science/hal-02929354/documentTest; https://univ-rennes.hal.science/hal-02929354/file/Neuzillet%20et%20al-2020-Fluropyrimidine%20single%20agent%20or%20doublet%20chemotherapy%20as%20second%20line%20treatment.pdfTest; PUBMED: 32525595 |
| DOI: | 10.1002/ijc.33146 |
| الإتاحة: | https://doi.org/10.1002/ijc.33146Test https://univ-rennes.hal.science/hal-02929354Test https://univ-rennes.hal.science/hal-02929354/documentTest https://univ-rennes.hal.science/hal-02929354/file/Neuzillet%20et%20al-2020-Fluropyrimidine%20single%20agent%20or%20doublet%20chemotherapy%20as%20second%20line%20treatment.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.986A60D6 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/ijc.33146 |
|---|